MGMedine Idrizoglu Gulcebi

Medine Idrizoglu Gulcebi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Medine Idrizoglu Gulcebi has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Elevated body temperature affects spike-and-wave discharges and induces behavioural deficits in genetic absence epilepsy rats

    by Seyhmus Gavas, Ceylin Yilmaz, Berk Erdogan, Enes Ipek, Berna Ozen, Ozlem Akman, James D. Mills, Annamaria Vezzani, Medine I. Gulcebi

  • Extreme ambient temperatures and seizure outcomes in children with epilepsy: insights from a survey in Turkey

    by Ismail Hakki Akbeyaz, Yekta Culpan, Seyhmus Gavas, Gulten Ozturk, Bilgihan Bikmazer, Zeynep Yilmaz, Bilgen B. Geckinli, James M. Mills, Francesco Fortunato, Dilsad Turkdogan, et al.

  • Open Access

    Climate change and hyponatremia‐related hospital admissions in people with focal epilepsy exposed to carbamazepine or its derivatives

    by Francesco Fortunato, Francesco D'Amico, Anny Votano, Ilaria Sammarra, Environmental Climate Observatory Group – CNR‐ISAC Lamezia Terme, Michele Trimboli, Medine I Gulcebi, James D Mills, Simona Balestrini, Sanjay M Sisodiya, et al.

    Objective: To estimate the proportion of individuals with focal epilepsy treated with at least one among carbamazepine (CBZ), oxcarbazepine (OXC), or eslicarbazepine (ESL), who were hospitalized due to hyponatremia‐related symptoms in 2024, and to test the hypothesis that there is an association with climatic variables. Methods: We undertook a prospective study in which people with focal epilepsy treated with at least one of the target drugs and at least one attendance in 2024 formed the study cohort. Individuals who were admitted or seen as outpatients for hyponatremia in 2024 were considered cases and the rest considered controls. Climate analysis was performed in Lamezia Terme, Calabria, Italy. Results: Seventeen of the entire cohort of 105 (16.2%) had hyponatremia‐related hospitalizations. Older age (odds ratio [OR] = 1.07, 95% confidence interval [CI] = 1.03–1.12; p = .001) and exposure to OXC/ESL compared to CBZ (OR = 4.15, 95% CI = 1.20–14.32; p = .02) emerged as significant predictors of the events. Thirteen of the 17 cases (76.5%) currently reside on the Calabria coastline. Twelve of 17 events (70.6%) occurred between June and August. Among climatic variables, heatwaves (OR = 4.87, 95% CI = 1.75–13.50; p = .002) and tropical nights (night‐temperature ≥20°C) (OR = 2.72, 95% CI = 1.02–7.27; p = .046) were the most significant predictors of the events. Forecasting models based on 10 consecutive days of recordings prior to the events revealed trends of rising temperatures preceding the events. Significance: We report a high rate of hyponatremia‐related hospitalizations among people with epilepsy occurring predominantly during summer. Climate change–related events, such as heatwaves and tropical nights, may trigger hyponatremia symptoms. Climate–regional vulnerability should therefore also be considered when selecting antiseizure medications and when counseling patients. We encourage interdisciplinary collaboration between clinicians and climate scientists in this emerging critical area.


  • Open Access

    Medications, epilepsy and climate change: Added layers of complexity

    by Medine I. Gulcebi, Seyhmus Gavas, Sanjay M. Sisodiya

    Climate change—the global crisis with pervasive health impacts—has adverse consequences for people with epilepsy (PWE) who have low quality of life due to poor seizure control, socioeconomic disadvantages and comorbidities. This review focuses on the potential effects of climate change on the pharmacological characteristics of antiseizure medications (ASMs), antipsychotics and antidepressants. We note that findings particularly obtained from physicochemical stability studies have been demonstrated experimentally for some specific environmental conditions whereas studies for clinical outcome effects are very limited. Carbamazepine, valproate, phenytoin or lorazepam appear to be ASMs at risk of being affected by high temperature and/or humidity. Even the stability of blood samples needs to be considered during transportation to therapeutic drug monitoring units, particularly for the PWE living in low‐income countries that are facing the most challenges of climate change effects attributed to low infrastructure and healthcare system capacity. We need more urgent research investigating drug responses of PWE regarding especially the effects of adverse weather events such as heatwaves on physicochemical stability or pharmacokinetics of drugs in a complex interaction with the vulnerabilities of individuals, accompanying neuropsychiatric disorders and geographical challenges. Then we will be able to develop pharmacological treatment strategies to improve the quality of life of PWE during adverse weather events.


  • Open Access

    Climate change and neurological diseases: report from the Hot Brain 2: Climate Change and Brain Health meeting, 2024

    by James D Mills, Medine I Gulcebi, Jo Allatt, Action Amos, Jack Atkinson, Jason Berwick, Susan Clayton, Derk-Jan Dijk, Kimberly C Doell, Kristie Ebi, et al.


  • Exploring the impact of climate change on epilepsy: Insights from the 15th European Epilepsy Congress

    by James Mills, Alessia Romagnolo, Giulia Battaglia, Sara Eyal, Medine I. Gulcebi, Bernadette Macrohon, Sanjay M. Sisodiya, Annamaria Vezzani, The Climate Change Commission Of The Ilae


  • Open Access

    Electron microscopic GABA evaluation in hippocampal mossy terminals of genetic absence epilepsy rats receiving kindling stimulations

    by Nuray Nükhet İmdat, Özlem Tuğçe ÇİLİNGİR-KAYA, Zehra Nur Turgan Âşik, Tuğba KARAMAHMUTOĞLU, Medine Gülçebi̇ İdri̇z Oğlu, Dilek Akakin, Filiz Onat, Serap Şi̇rvanci

    Objective: The hypotheses related to the fact of epileptic mechanisms are mainly based on excitation-inhibition imbalance in central nervous system. GAERS (Genetic Absence Epilepsy Rats from Strasbourg) is a well-known animal model of absence epilepsy, and frequently used in experimental studies. In the present study, we aimed to examine possible morphological and gamma-aminobutyric acid (GABA) density changes in GAERS hippocampus after electrical kindling stimulations. Methods: All control and test group rats received 6 kindling stimulations. Rats were decapitated 1 h after the last stimulation. Ultrastructural GABA immunocytochemistry was used to evaluate GABA density quantitatively in mossy terminals of hippocampal CA3 region. Results: GABA levels were less in kindling groups compared to their controls, and in GAERS groups compared to Wistar groups; mitochondrial and dendritic spine area ratios were greater in GAERS groups compared to Wistar groups, although all these evaluations were statistically nonsignificant. Depletion of synaptic vesicles was evident in the mossy terminals of kindling groups. Conclusion: The reason of decreased levels of GABA found in the present study might be that GABA has been released from the synaptic pool rapidly at an early time period after the last stimulation, for compansation mechanisms. Depletion of synaptic vesicles observed in kindling groups shows that even 6 kindling stimulations have an impact of changing hippocampal morphology in trisynaptic cycle. The increased mitochondrial area in GAERS might be related to the increased mitochondrial activity. The increased dendritic spine area might be related to the increased performance of learning in GAERS. Our findings indicating that absence epilepsy and temporal lobe epilepsy have different mechanisms of epileptogenesis might be a basis for further experimental studies


  • Open Access

    Pharmacokinetic characterization of favipiravir in patients with COVID‐19

    by Rezzan Gülhan, Emel Eryüksel, Medine Gülçebi İdRiz Oğlu, Yekta Çulpan, Aylin Toplu, Derya Kocakaya, Elif Tigen, Buket Ertürk Şengel, Uluhan Sili, Şehnaz Olgun Yıldızeli, et al.

    This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID‐19 with a positive RT‐PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in‐hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID‐19. The median favipiravir trough concentration (C0‐trough) on Day 2 was 21.26 (interquartile range [IQR], 8.37–30.78) μg/mL, whereas it decreased significantly to 1.61 (IQR, 0.00–6.41) μg/mL on Day 4, the area under the concentration–time curve decreased by 68.5%. Day 2 C0‐trough of female patients was higher than male patients. Our findings indicate that favipiravir concentrations show significant variability during the treatment of COVID‐19 and therapeutic drug monitoring may be necessary to maintain targeted concentrations.


  • Climate change and epilepsy: Insights from clinical and basic science studies

    by Medine I. Gulcebi, Emanuele Bartolini, Omay Lee, Christos Panagiotis Lisgaras, Filiz Onat, Janet Mifsud, Pasquale Striano, Annamaria Vezzani, Michael S. Hildebrand, Diego Jimenez-Jimenez, et al.


  • Potential drug–drug interactions among prescriptionsfor elderly patients in primary health care

    by Zafer Gören, Mahluga J. Demirkapu, Gökçe Akpinar Acet, Sanda Çali, Medine Gülçebi Idriz Oğlu

    Background/aim: Elderly patients are at high risk from drug-drug interactions (DDIs). This study evaluates the potential DDIs in Turkish elderly patients at a primary health care outpatient clinic. Materials and methods: Online database systems were used to examine DDIs on the prescriptions of patients (n = 1206). The clinical severity of DDIs was classified by the Lexi-Interact Online database. Results: Of the 5059 prescriptions, 33% were found to have DDIs. We detected 29 (0.9%) A, 380 (11.8%) B, 2494 (77.7%) C, 289 (9%) D, and 18 (0.6%) X risk rating category DDIs among the prescriptions. Prescriptions of female patients and patients aged between 65 and 72 years showed significantly higher number of DDIs. The frequency of DDIs increased both with the number of drugs and combined preparations per prescription. Acetylsalicylic acid and salbutamol were the most frequently prescribed drugs contributing to clinically important DDIs. Additionally, acetylsalicylic acid and escitalopram, which interact with each other, were found on the list of Beers criteria. The most predicted clinical outcomes of DDIs were increase in therapeutic efficacy and adverse/toxic reactions. Conclusions: Prediction of DDIs in elderly patients will provide better prescribing and drug safety. Use of nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, and beta-2 adrenergic receptor agonists should be closely monitored.